Cookie Policy

We've put some small files called essential cookies on your device to help our site work on your browser.
We also use analytical cookies to help up improve our website by collecting and reporting information on it's usage.

You can read more above this on our Privacy Policy page.

I'm ok with analytical cookies Do not use analytics cookies

Shield reports recently presented supportive data from real-world clinical use of Feraccru® (Ferric Maltol)

28 Jun 2018

Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients’ unmet medical needs, today reports on recent presentations of results from two studies of the use of Feraccru in clinical practice.  The FRESH study (Feraccru® Real World Effectiveness Study in Hospital Practice) was presented at the British Society of Gastroenterology in Liverpool and data from a health economic study has been presented at the recent European Haematology Association meeting in Stockholm.  Feraccru is a novel oral ferric iron therapy that is approved and marketed in Europe for the treatment of iron deficiency (ID).

For more information please see the press release below:


Back to news